CY1119086T1 - Σταθεροποιημενες υδατικες συνθεσεις των νευρομυικων ανασταλτικων παραγοντων - Google Patents
Σταθεροποιημενες υδατικες συνθεσεις των νευρομυικων ανασταλτικων παραγοντωνInfo
- Publication number
- CY1119086T1 CY1119086T1 CY20171100585T CY171100585T CY1119086T1 CY 1119086 T1 CY1119086 T1 CY 1119086T1 CY 20171100585 T CY20171100585 T CY 20171100585T CY 171100585 T CY171100585 T CY 171100585T CY 1119086 T1 CY1119086 T1 CY 1119086T1
- Authority
- CY
- Cyprus
- Prior art keywords
- quaternary ammonium
- present
- aquatic
- relates
- aqueous composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 11
- 229920001273 Polyhydroxy acid Polymers 0.000 abstract 5
- 125000001453 quaternary ammonium group Chemical group 0.000 abstract 5
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 3
- 150000002596 lactones Chemical class 0.000 abstract 3
- 239000003112 inhibitor Substances 0.000 abstract 2
- 239000007788 liquid Substances 0.000 abstract 2
- 230000002232 neuromuscular Effects 0.000 abstract 2
- 239000000842 neuromuscular blocking agent Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000006641 stabilisation Effects 0.000 abstract 1
- 238000011105 stabilization Methods 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurology (AREA)
- Anesthesiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Η παρούσα εφεύρεση αφορά σε υδατική σύνθεση περιλαμβάνουσα: (i) τεταρτοταγούς αμμωνίου νευρομυϊκό ανασταλτικό παράγοντα και (ii) έκδοχο επιλεγόμενο από πολυυδρόξυ οξύ του ακόλουθου τύπου: HO-CH2-[CH(ΟH)]n-COOH, όπου n είναι ακέραιος από 1 έως 8, ενδομοριακή λακτόνη του εν λόγω πολυυδρόξυ οξέος ή μείγμα αυτών. Περαιτέρω, η παρούσα εφεύρεση αφορά σε υγρή φαρμακευτική σύνθεση περιλαμβάνουσα ή συνιστάμενη από την εν λόγω υδατική σύνθεση και μέθοδο για παρασκευή της εν λόγω υδατικής σύνθεσης που περιλαμβάνει τα στάδια: a) παροχής τεταρτοταγούς αμμωνίου νευρομυϊκού ανασταλτικού παράγοντα, όπου ο εν λόγω τεταρτοταγούς αμμωνίου νευρομυϊκός ανασταλτικός παράγων προαιρετικά είναι λυοφιλισμένος· b) παροχής ενός εκδόχου που επιλέγεται από πολυυδρόξυ οξύ του ακολούθου τύπου: HO-CH2-[CH(OH)]n-COOH, όπου n είναι ακέραιος από 1 έως 8, ενδομοριακή λακτόνη του εν λόγω πολυυδρόξυ οξέος ή μείγμα αυτών, όπου το εν λόγω έκδοχο προαιρετικά είναι λυοφιλισμένο, c) ανάμειξης του τεταρτοταγούς αμμωνίου νευρομυϊκού ανασταλτικού παράγοντα του σταδίου a) και του εκδόχου του σταδίου b) σε νερό για να δώσουν υδατική σύνθεση. Επιπλέον, η παρούσα εφεύρεση αφορά στην χρήση πολυυδροξυκαρβοξυλικού οξέος του παρακάτω τύπου: HO-CH2- [CH(OH)]n-COOH, όπου n είναι ακέραιος από 1 έως 8, ενδομοριακής λακτόνης του εν λόγω πολυυδρόξυ οξέος ή μείγματος αυτών για σταθεροποίηση υδατικής σύνθεσης που περιλαμβάνει τεταρτοταγούς αμμωνίου νευρομυϊκό ανασταλτικό παράγοντα. Η παρούσα εφεύρεση επίσης αφορά σε έναν περιέκτη που περιέχει την υδατική σύνθεση ή την υγρή φαρμακευτική σύνθεση της παρούσας εφεύρεσης. Περαιτέρω αφορά σε ένα κιτ που περιλαμβάνει τις εν λόγω συνθέσεις. Προτιμώμενες πραγματοποιήσεις είναι προφανείς από τις εξαρτώμενες αξιώσεις.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12186393.0A EP2712611A1 (en) | 2012-09-27 | 2012-09-27 | Stabilized aqueous compositions of neuromuscular blocking agents |
| EP13766501.4A EP2900216B1 (en) | 2012-09-27 | 2013-09-19 | Stabilized aqueous compositions of neuromuscular blocking agents |
| PCT/EP2013/069507 WO2014048836A1 (en) | 2012-09-27 | 2013-09-19 | Stabilized aqueous compositions of neuromuscular blocking agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1119086T1 true CY1119086T1 (el) | 2018-01-10 |
Family
ID=47046351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171100585T CY1119086T1 (el) | 2012-09-27 | 2017-06-02 | Σταθεροποιημενες υδατικες συνθεσεις των νευρομυικων ανασταλτικων παραγοντων |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20150216979A1 (el) |
| EP (2) | EP2712611A1 (el) |
| JP (1) | JP6347784B2 (el) |
| KR (1) | KR102138392B1 (el) |
| CN (1) | CN104519872B (el) |
| AU (1) | AU2013322897B2 (el) |
| BR (1) | BR112015000688B1 (el) |
| CA (1) | CA2878714C (el) |
| CY (1) | CY1119086T1 (el) |
| ES (1) | ES2628076T3 (el) |
| IL (1) | IL236042A (el) |
| MX (1) | MX356212B (el) |
| PL (1) | PL2900216T3 (el) |
| PT (1) | PT2900216T (el) |
| RS (1) | RS56060B1 (el) |
| RU (1) | RU2695226C2 (el) |
| TW (1) | TWI595876B (el) |
| WO (1) | WO2014048836A1 (el) |
| ZA (1) | ZA201408945B (el) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2016016148A (es) * | 2014-06-26 | 2017-04-25 | Maruishi Pharma | Preparacion de rocuronio con estabilidad mejorada. |
| JP2016121073A (ja) * | 2014-12-24 | 2016-07-07 | ニプロ株式会社 | 注射剤用医薬組成物の製造方法 |
| WO2022078483A1 (zh) * | 2020-10-15 | 2022-04-21 | 江苏恩华络康药物研发有限公司 | 甾体季铵化合物及其制备方法、制剂和用途 |
| US20230014293A1 (en) * | 2021-07-02 | 2023-01-19 | Fresenius Kabi Austria Gmbh | Aqueous, room-temperature stable rocuronium composition |
| EP4371553A1 (en) * | 2022-11-16 | 2024-05-22 | B. Braun Melsungen AG | Composition comprising rocuronium |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2681863B1 (fr) | 1991-09-27 | 1995-02-03 | Rhone Dpc Europ | Solution de sparfloxacine sa preparation et sel la constituant. |
| IT1271031B (it) | 1994-10-21 | 1997-05-26 | Poli Ind Chimica Spa | Composizioni farmaceutiche miorilassanti |
| WO2000044334A2 (en) * | 1999-01-28 | 2000-08-03 | Dinesh Shantilal Patel | Novel injectable muscle relaxant formulations |
| US20060229258A1 (en) * | 2003-07-30 | 2006-10-12 | Daniela Serikaku | Steroidal compositions containing hydroxycarboxylic acids and methods of using the same |
| DE10337710A1 (de) * | 2003-08-16 | 2005-03-10 | Supramol Parenteral Colloids | Amiodaron enthaltende Infusions- und Injektionslösungen |
| MY141763A (en) * | 2003-09-18 | 2010-06-30 | Novartis Ag | Pharmaceutical products comprising bisphosphonates |
| US20060148841A1 (en) * | 2004-02-26 | 2006-07-06 | Lundeen James E | Pharmaceutical composition comprising combination of non-alkaloid and alkaloid-based component for treating skeletal muscle spasm |
| US20060275331A1 (en) * | 2004-08-31 | 2006-12-07 | Borek Zaludek | Pharmaceutical composition, method of manufacturing and therapeutic use thereof |
| EP1874319A2 (en) | 2005-04-15 | 2008-01-09 | Lyotropic Therapeutics, Inc. | Formulations of quaternary ammonium neuromuscular blocking agents |
| CN1864667B (zh) * | 2006-06-02 | 2010-10-06 | 重庆医药工业研究院有限责任公司 | 一种稳定的罗库溴铵冻干制剂及其制备方法 |
| KR101403105B1 (ko) | 2006-10-31 | 2014-06-09 | 엘지전자 주식회사 | 귀환 데이터 전송 방법, 귀환 데이터 생성 방법 및 데이터스케줄링 방법 |
| WO2008065142A1 (en) | 2006-11-29 | 2008-06-05 | N.V. Organon | Stabilized solution of rocuronium comprising a sulfoalkyl-ether-beta-cyclodextrin derivative |
| CZ300664B6 (cs) * | 2007-01-22 | 2009-07-15 | Pliva-Lachema A. S. | Sterilní kapalná farmaceutická kompozice a zpusob její výroby |
| KR20090102844A (ko) * | 2007-01-22 | 2009-09-30 | 플리바-라케마 에이. 에스. | 알콜 당-계 완충액을 함유한 옥살리플라틴 약제학적 조성물 |
| KR101024742B1 (ko) * | 2007-12-31 | 2011-03-24 | 주식회사 삼양사 | 탁산 함유 양친성 블록 공중합체 미셀 조성물 및 그 제조방법 |
| US20100082749A1 (en) | 2008-09-26 | 2010-04-01 | Yahoo! Inc | Retrospective spam filtering |
| CN101653412B (zh) * | 2009-09-15 | 2014-06-25 | 尹双保 | 一种稳定的罗库溴铵注射液 |
| AU2010339689B2 (en) | 2010-01-07 | 2015-02-19 | Alkermes Pharma Ireland Limited | Quaternary ammonium salt prodrugs |
| EP2462913A1 (en) * | 2010-12-10 | 2012-06-13 | Fresenius Medical Care Deutschland GmbH | Insert and vial for the infusion of liquids |
-
2012
- 2012-09-27 EP EP12186393.0A patent/EP2712611A1/en not_active Withdrawn
-
2013
- 2013-09-19 CN CN201380042469.5A patent/CN104519872B/zh active Active
- 2013-09-19 JP JP2015533539A patent/JP6347784B2/ja active Active
- 2013-09-19 WO PCT/EP2013/069507 patent/WO2014048836A1/en not_active Ceased
- 2013-09-19 BR BR112015000688-4A patent/BR112015000688B1/pt active IP Right Grant
- 2013-09-19 MX MX2015004056A patent/MX356212B/es active IP Right Grant
- 2013-09-19 RS RS20170581A patent/RS56060B1/sr unknown
- 2013-09-19 ES ES13766501.4T patent/ES2628076T3/es active Active
- 2013-09-19 RU RU2015115430A patent/RU2695226C2/ru active
- 2013-09-19 PL PL13766501T patent/PL2900216T3/pl unknown
- 2013-09-19 CA CA2878714A patent/CA2878714C/en active Active
- 2013-09-19 KR KR1020157007764A patent/KR102138392B1/ko active Active
- 2013-09-19 AU AU2013322897A patent/AU2013322897B2/en active Active
- 2013-09-19 US US14/420,684 patent/US20150216979A1/en not_active Abandoned
- 2013-09-19 PT PT137665014T patent/PT2900216T/pt unknown
- 2013-09-19 EP EP13766501.4A patent/EP2900216B1/en active Active
- 2013-09-25 TW TW102134492A patent/TWI595876B/zh active
-
2014
- 2014-12-03 IL IL236042A patent/IL236042A/en active IP Right Grant
- 2014-12-05 ZA ZA2014/08945A patent/ZA201408945B/en unknown
-
2017
- 2017-06-02 CY CY20171100585T patent/CY1119086T1/el unknown
-
2019
- 2019-07-18 US US16/515,653 patent/US11998605B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL236042A0 (en) | 2015-01-29 |
| AU2013322897B2 (en) | 2017-07-27 |
| RU2695226C2 (ru) | 2019-07-22 |
| ES2628076T3 (es) | 2017-08-01 |
| IL236042A (en) | 2017-06-29 |
| KR20150058259A (ko) | 2015-05-28 |
| MX356212B (es) | 2018-05-18 |
| PL2900216T3 (pl) | 2017-10-31 |
| KR102138392B1 (ko) | 2020-07-28 |
| US20150216979A1 (en) | 2015-08-06 |
| WO2014048836A1 (en) | 2014-04-03 |
| CA2878714C (en) | 2021-04-27 |
| BR112015000688A2 (pt) | 2017-06-27 |
| US20200000925A1 (en) | 2020-01-02 |
| CA2878714A1 (en) | 2014-04-03 |
| PT2900216T (pt) | 2017-06-23 |
| RS56060B1 (sr) | 2017-10-31 |
| CN104519872B (zh) | 2017-12-01 |
| JP6347784B2 (ja) | 2018-06-27 |
| EP2900216B1 (en) | 2017-04-26 |
| AU2013322897A1 (en) | 2015-01-29 |
| ZA201408945B (en) | 2015-11-25 |
| HK1205694A1 (en) | 2015-12-24 |
| JP2015531359A (ja) | 2015-11-02 |
| CN104519872A (zh) | 2015-04-15 |
| EP2712611A1 (en) | 2014-04-02 |
| RU2015115430A (ru) | 2016-11-20 |
| MX2015004056A (es) | 2015-07-06 |
| TW201412317A (zh) | 2014-04-01 |
| EP2900216A1 (en) | 2015-08-05 |
| US11998605B2 (en) | 2024-06-04 |
| BR112015000688B1 (pt) | 2022-02-15 |
| TWI595876B (zh) | 2017-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124239T1 (el) | Ενωσεις αμινο-τριαζολοπυριδινης και χρηση αυτων στην αγωγη του καρκινου | |
| CY1124500T1 (el) | Συνθεση που περιλαμβανει αντισωμα που δεσμευεται με περιοχη ii toy her2 και οξινες παραλλαγες αυτου | |
| CY1124068T1 (el) | Στερεες μορφες ενος εκλεκτικου αναστολεα cdk4/6 | |
| CY1121418T1 (el) | Παρεμποδιστες ιου ηπατιτιδας c | |
| CY1120031T1 (el) | Αποπτωτικοι υποκινητες ν-ακυλοσουλφοναμιδης | |
| CY1122611T1 (el) | Ενωσεις πυραζολοπυριμιδινης ως αναστολεις κινασης | |
| CY1117352T1 (el) | Υποκατεστημενες ιμιδαζοπυριδαζiνες | |
| MX395362B (es) | Edulcorantes de alta intensidad | |
| EA201591890A1 (ru) | Производные n-фенилкарбоксамида и их применение в качестве лекарственных препаратов для лечения гепатита b | |
| CY1120104T1 (el) | Αναστολεις της syk | |
| CY1123627T1 (el) | Παραγωγα διυδροϊμιδαζοπυραζινονης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου | |
| EA201592198A1 (ru) | Производные сульфамоилтиофенамида и их применение в качестве медикаментов для лечения гепатита b | |
| EA201490357A1 (ru) | Индазолы | |
| EA201691590A1 (ru) | Бензимидазол-2-амины в качестве ингибиторов midhi | |
| CY1119433T1 (el) | Αμινο-υποκατεστημενες ιμιδαζοπυριδαζινες | |
| EA201491179A1 (ru) | 2',4'-дифтор-2'-метил замещенные нуклеозидные производные в качестве ингибиторов репликации рнк вируса гепатита с | |
| EA201491672A1 (ru) | Гетероциклильные соединения как ингибиторы mek | |
| MX2016016515A (es) | Derivados de auristatina y conjugados de los mismos. | |
| DOP2011000199A (es) | Compuestos heterociclocos y metodos de uso | |
| EA201490846A1 (ru) | Новые производные арилхинолина | |
| CY1116439T1 (el) | Τριαζολοπυριδινες | |
| CY1113676T1 (el) | Υποκατεστημενο βητα-φαινυλο-αλφα-υδροξυ προπιονικο οξυ, μεθοδος συνθεσης και χρηση του | |
| CY1116775T1 (el) | Παραγωγα πυριμιδονης ως αναστολεις της ιστικης τρανσγλουταμινασης | |
| EA201591451A1 (ru) | Модуляторы flap | |
| EA201691141A1 (ru) | Соединения против ccr6 |